Elizabeth Brem, MD, of UCI Health, explains how the OLYMPIA-1 study, evaluating odronextamab versus investigator’s choice in patients with previously untreated follicular lymphoma aligns with a new paradigm shift. Dr. Brem outlines the study’s potential impact on therapeutic strategies. She also offers expert perspectives on future decision-making between bispecific antibodies and chimeric antigen receptor T-cell therapies, ad how to sequence the influx of new therapies.
Moving Bispecific Antibodies Upfront in Follicular Lymphoma
By Elizabeth Brem, MD - Last Updated: January 14, 2025Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.